Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and a threat to the elderly and immunocompromised.
• Previous formalin-inactivated (FI)-RSV vaccination in children led to enhanced disease and pulmonary eosinophilia, linked to an overactive Th2 immune response.
• The lack of a licensed RSV vaccine underscores the need for research into preventing vaccine-associated disease.

Purpose of the Study:

• To investigate the mechanisms behind enhanced RSV disease following prior immunization.
• To evaluate the role of T cell responses, specifically CD4 and CD8 T cells, in vaccine-associated RSV disease.
• To utilize a BALB/c mouse model that mimics human RSV infection for vaccine development studies.

Main Methods:

• BALB/c mice were immunized with FI-RSV or a recombinant vaccinia virus (vv) expressing the RSV G glycoprotein.
• Mice were subsequently challenged with RSV to assess lung inflammation, injury, and pulmonary eosinophilia.
• The role of CD4 T cells was examined by depleting them and observing the effect on eosinophilia.
• The potential inhibitory effect of RSV-specific CD8 T cells on Th2-mediated responses was investigated.

Main Results:

• Mice immunized with FI-RSV or vvG showed exacerbated lung inflammation, injury, and eosinophilia upon RSV challenge.
• Depletion of CD4 T cells secreting Th2 cytokines abolished pulmonary eosinophilia, confirming their necessity for the enhanced disease.
• Preliminary findings suggest that RSV-specific CD8 T cells may inhibit Th2-mediated pulmonary eosinophilia in vvG-primed mice.

Conclusions:

• The BALB/c mouse model effectively replicates human RSV disease and vaccine-associated complications.
• Understanding the balance between Th2 and CD8 T cell responses is crucial for designing safe and effective RSV vaccines.
• Further research into CD8 T cell mechanisms could offer novel strategies for preventing vaccine-induced adverse effects.